AstraZeneca PLC (AZN)vsLive Nation Entertainment Inc (LYV)
AZN
AstraZeneca PLC
$185.78
+0.93%
HEALTHCARE · Cap: $284.63B
LYV
Live Nation Entertainment Inc
$154.92
+1.45%
COMMUNICATION SERVICES · Cap: $35.85B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 133% more annual revenue ($58.74B vs $25.20B). AZN leads profitability with a 17.4% profit margin vs 2.0%. AZN appears more attractively valued with a PEG of 1.50. AZN earns a higher WallStSmart Score of 66/100 (B-).
AZN
Strong Buy66
out of 100
Grade: B-
LYV
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.8%
Fair Value
$306.07
Current Price
$185.78
$120.29 discount
Intrinsic value data unavailable for LYV.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Every $100 of equity generates 37 in profit
Areas to Watch
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
2.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Trading at 133.6x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : LYV
The strongest argument for LYV centers on Return on Equity. Revenue growth of 11.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.
Bear Case : LYV
The primary concerns for LYV are Profit Margin, Piotroski F-Score, PEG Ratio. Thin 2.0% margins leave little buffer for downturns.
Key Dynamics to Monitor
LYV carries more volatility with a beta of 1.15 — expect wider price swings.
LYV is growing revenue faster at 11.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (66/100 vs 47/100), backed by strong 17.4% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Live Nation Entertainment Inc
COMMUNICATION SERVICES · ENTERTAINMENT · USA
Live Nation Entertainment, Inc is an American global entertainment company, founded in 2010, following the merger of Live Nation and Ticketmaster. The company promotes, operates, and manages ticket sales for live entertainment in the United States and internationally. It also owns and operates entertainment venues, and manages the careers of music artists.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?